IGM Biosciences (NASDAQ:IGMS) Shares Gap Down to $20.96
IGM Biosciences (NASDAQ:IGMS) Shares Gap Down to $20.96
IGM Biosciences, Inc. (NASDAQ:IGMS – Get Rating)'s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $20.96, but opened at $20.48. IGM Biosciences shares last traded at $21.21, with a volume of 556 shares trading hands.
IGM Biosciences，Inc.(納斯達克代碼：IGMS-GET Rating)的股價週三盤前大幅下跌。該股此前收於20.96美元，但開盤報20.48美元。IGM Biosciences的股票最新報21.21美元，總成交量為556股。
Wall Street Analysts Forecast Growth
華爾街分析師預測經濟增長
IGMS has been the subject of several recent research reports. Bank of America initiated coverage on IGM Biosciences in a report on Monday, August 29th. They set a "buy" rating and a $34.00 price target for the company. Truist Financial lowered their target price on shares of IGM Biosciences from $74.00 to $37.00 and set a "buy" rating on the stock in a report on Tuesday, August 23rd. Guggenheim cut their price target on shares of IGM Biosciences to $40.00 in a report on Monday, August 15th. Finally, Robert W. Baird lowered their price objective on IGM Biosciences from $46.00 to $31.00 and set an "outperform" rating on the stock in a report on Wednesday, June 1st. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $53.00.
IGMS是最近幾份研究報告的主題。美國銀行在8月29日星期一的一份報告中發起了對IGM Biosciences的報道。他們為該公司設定了“買入”評級和34.00美元的目標價。Truist Financial在8月23日(週二)的一份報告中將IGM Biosciences的股票目標價從74.00美元下調至37.00美元，並對該股設定了“買入”評級。古根海姆在8月15日星期一的一份報告中將IGM Biosciences的股票目標價下調至40.00美元。最後，羅伯特·W·貝爾德在6月1日星期三的一份報告中將IGM Biosciences的目標價從46.00美元下調至31.00美元，並對該股設定了“跑贏大盤”的評級。兩名分析師對該股的評級為持有，七名分析師對該股的評級為買入。根據MarketBeat.com，該公司目前的平均評級為“中等買入”，平均目標價為53.00美元.
IGM Biosciences Price Performance
IGM生物科學價格表現
The business has a 50-day moving average price of $20.24 and a two-hundred day moving average price of $18.71.
該業務的50日移動均線價格為20.24美元，200日移動均線價格為18.71美元。
Insider Activity
內幕活動
In related news, insider Bruce Keyt sold 5,000 shares of IGM Biosciences stock in a transaction dated Tuesday, September 6th. The stock was sold at an average price of $19.06, for a total transaction of $95,300.00. Following the completion of the sale, the insider now owns 39,489 shares in the company, valued at approximately $752,660.34. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders have sold 30,000 shares of company stock worth $622,107 over the last three months. 55.96% of the stock is currently owned by corporate insiders.
在相關新聞中，內部人士Bruce KEYT在一筆日期為9月6日(星期二)的交易中出售了5,000股IGM Biosciences股票。該股以19.06美元的平均價格出售，總成交金額為95,300.00美元。出售完成後，這位內部人士現在擁有該公司39,489股，價值約752,660.34美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，該文件可在以下網址獲得美國證券交易委員會網站。在過去的三個月裏，內部人士已經出售了3萬股公司股票，價值622,107美元。55.96%的股份目前由企業內部人士持有。
Institutional Trading of IGM Biosciences
IGM生物科學的制度性交易
Several hedge funds and other institutional investors have recently added to or reduced their stakes in IGMS. American International Group Inc. increased its position in IGM Biosciences by 15.0% during the second quarter. American International Group Inc. now owns 4,684 shares of the company's stock worth $84,000 after purchasing an additional 612 shares during the last quarter. DekaBank Deutsche Girozentrale increased its holdings in shares of IGM Biosciences by 9.6% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 9,100 shares of the company's stock worth $235,000 after buying an additional 800 shares during the last quarter. Point72 Hong Kong Ltd purchased a new position in shares of IGM Biosciences in the 4th quarter worth $34,000. Rhumbline Advisers boosted its holdings in IGM Biosciences by 16.5% in the first quarter. Rhumbline Advisers now owns 9,222 shares of the company's stock valued at $247,000 after acquiring an additional 1,308 shares during the last quarter. Finally, Amalgamated Bank purchased a new stake in IGM Biosciences during the first quarter valued at about $36,000. Hedge funds and other institutional investors own 41.20% of the company's stock.
幾家對衝基金和其他機構投資者最近增持或減持了IGMS的股份。美國國際集團在第二季度將其在IGM Biosciences的頭寸增加了15.0%。美國國際集團目前持有該公司4,684股股票，價值84,000美元，此前該公司在上個季度又購買了612股。DekaBank Deutsche Girozentrale在第一季度增持了9.6%的IGM Biosciences股票。DekaBank Deutsche Girozentrale在上個季度又購買了800股，現在擁有9,100股該公司股票，價值23.5萬美元。Point72 Hong Kong Ltd在第四季度購買了價值34,000美元的IGM Biosciences新股頭寸。Rhumbline Advisers在第一季度將其在IGM Biosciences的持有量增加了16.5%。Rhumbline Advisers在上個季度增持了1,308股後，現在擁有9,222股該公司的股票，價值24.7萬美元。最後，合併銀行在第一季度購買了IGM Biosciences的新股份，價值約3.6萬美元。對衝基金和其他機構投資者持有該公司41.20%的股票。
IGM Biosciences Company Profile
IGM生物科學公司簡介
(Get Rating)
(獲取評級)
IGM Biosciences, Inc, a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL).
IGM生物科學公司是一家生物技術公司，開發用於治療癌症、傳染病、自身免疫性疾病和炎症性疾病的免疫球蛋白M(IgM)抗體。該公司的主要候選產品是IGM-2323，這是一種雙特異性IgM抗體，正處於第二階段臨牀試驗，用於治療復發/難治性B細胞非霍奇金淋巴瘤(NHL)患者。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on IGM Biosciences (IGMS)
- General Mills: Superior Returns With Less Volatility
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- Is Ford Rolling To A Rebound After Its Q3 Warning
- 免費獲取StockNews.com關於IGM生物科學的研究報告(IGMS)
- 通用磨坊：波動性更小、回報更高
- 連續60年提高股息的3只防御性股票
- 3家航空公司股票陷入持有格局
- Roku股票下跌，但並未出局
- 福特在第三季度發出警告後是否正在反彈
Receive News & Ratings for IGM Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IGM Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受IGM《生物科學日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對IGM Biosciences和相關公司的最新新聞和分析師評級的每日簡明摘要。